Australia markets open in 8 hours 23 minutes
  • ALL ORDS

    7,689.40
    -17.80 (-0.23%)
     
  • AUD/USD

    0.7156
    -0.0013 (-0.18%)
     
  • ASX 200

    7,384.50
    -20.90 (-0.28%)
     
  • OIL

    71.83
    -0.53 (-0.73%)
     
  • GOLD

    1,783.00
    -2.50 (-0.14%)
     
  • BTC-AUD

    68,346.95
    -2,118.22 (-3.01%)
     
  • CMC Crypto 200

    1,276.23
    -29.72 (-2.28%)
     

Beroni Group Limited (BTG.NSX) US$1.07M COVID-19 Antigen Test Kits Order from Japan

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
Beroni Group Limited
Beroni Group Limited

Beroni Group Limited (BTG.NSX) US$1.07M COVID-19 Antigen Test Kits Order from Japan

New York, United States, Nov 18, 2021 - (ABN Newswire) - Beroni Group (OTCMKTS:BNIGF) (NSX:BTG), an Australia-based diversified biopharmaceutical enterprise focused on the research, development, innovation and commercialization of therapies and products for treatment of global diseases, announced that it has received part payment of a US$1.07M (JPY117.5M) order for its SARS-CoV-2 Antigen Test Kit from a Japanese pharmaceutical company based in Tokyo. Beroni has so far produced and delivered about two thirds of the test kits to the buyer.

The SARS-CoV-2 Antigen Test Kit (Colloidal Gold Method) optimizes the sample collection process. It requires no blood, and only a nasopharyngeal swab is needed to collect samples. This greatly improves the convenience of testing and the test results can be obtained within 10 minutes. The antigen test kit was prepared using colloidal gold solidphase immunochromatography and is used for qualitative assays of SARS-CoV-2 antigen samples in vitro. Based on the latest clinical study, it demonstrated an overall sensitivity of 95% and specificity of 100% and has received CE certification in December 2020.

Recent COVID-19 cases and deaths have fallen dramatically throughout Japan as vaccinations have increased to cover more than 70% of the population. Japan has been using rapid antigen tests as one of the tools to contain outbreaks. "Widespread rapid testing for COVID-19 disease is absolutely critical for saving lives and reopening the economy. Our antigen detection kit provides an effective and convenient detection solution for clinics, employers, schools, and others seeking a safer reopening," said Jacky Zhang, Chairman, and CEO of Beroni Group.


About Beroni Group Limited:


Beroni Group (NSX:BTG) (OTCMKTS:BNIGF) is an international biopharmaceutical enterprise dedicated to the innovation and commercialization of drugs and therapies to combat various global diseases such as cancer and infectious diseases. Its diversified portfolio is comprised of a US FDA approved virus diagnostic kit, an e-commerce platform for the sale of pharmaceutical products and a development pipeline targeting oncology and cell therapies. Beroni has operations in Australia, United States, China and Japan. To learn more about Beroni, please visit www.beronigroup.com.

Contact:

Dragon Gate Investment Partners LLC
Tel: +1(646)-801-2803
Email: BNIGF@dgipl.com

Source:
Beroni Group Limited

Copyright (C) 2021 ABN Newswire. All rights reserved.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting